Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.75 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.75 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.75 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.75 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.75 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.75 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.75 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.75 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.75 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.75 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.75 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.75 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd2461 SCHEMBL77012 | 1.00 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| Azd2461 SCHEMBL29360368 | 1.00 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852674 | 0.97 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852672 | 0.95 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL31311843 | 0.92 | PARP1 (0.85) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL76871 | 0.91 | PARP1 (0.84) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL87500 | 0.91 | PARP1 (0.84) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852677 | 0.91 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL78156 | 0.91 | PARP1 (0.83) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL86912 | 0.91 | PARP1 (0.82) | PARP1PRAP1TNKSADORA1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-07-10 | — | — | US | claimed |
| US-20250100977-A1 | MERCAPTOPYRIMIDINE COMPOUNDS THAT INHIBIT NONHOMOLOGOUS END JOINING AND METHODS THEREOF | UNIVERSITY OF MYSORE (IN) | 2025-03-27 | — | — | US | claimed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | claimed |
| EP-4479046-A2 | METHODS TO PREVENT THERAPY RESISTANCE IN MELANOMA VIA BLOCKING GENOMIC INSTABILITY | The Regents of University of California (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | claimed |
| WO-2024216115-A1 | METHODS FOR PRODUCING A SUPER CENTRAL MEMORY CD8 T CELL SUBTYPE BY POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITION AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024186926-A1 | STRATEGIES TO PREVENT THE EVOLUTION OF LETHAL, MULTI-THERAPY-RESISTANT, WIDELY METASTATIC CUTANEOUS MELANOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-12 | — | — | WO | claimed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2023158911-A2 | METHODS TO PREVENT THERAPY RESISTANCE IN MELANOMA VIA BLOCKING GENOMIC INSTABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023126980-A1 | MERCAPTOPYRIMIDINE COMPOUNDS THAT INHIBIT NONHOMOLOGOUS END JOINING AND METHODS THEREOF | INDIAN INSTITUTE OF SCIENCE (IN) | 2023-07-06 | — | — | WO | claimed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | claimed |
| EP-3808749-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES | VERTEX PHARMA (US) | 2023-03-08 | — | — | EP | claimed |
| EP-4065097-A1 | PARTHANATOS CELL DEATH INHIBITORS FOR USE IN THE TREATMENT OF PSORIASIS | Universidad De Murcia (ES) | 2022-10-05 | — | — | EP | claimed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | claimed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20220233521-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | CD38, PARP1, PARP11 | PARP1 2/4885PRAP1 467/4885TNKS 47/4885 |
| US-20250100977-A1 | MERCAPTOPYRIMIDINE COMPOUNDS THAT INHIBIT NONHOMOLOGOUS END JOINING AND METHODS THEREOF | LIG4, LIG1, LIG3 | PARP1 39/4885PRAP1 1737/4885TNKS 120/4885 |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PARP1 339/4885PRAP1 2202/4885TNKS 44/4885 |
| US-20220233521-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | ATR, CHEK1, CHEK2 | PARP1 159/4885PRAP1 1889/4885TNKS 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.